PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: A61K 31/54, 31/403, 9/28	A3	(11) International Publication Number:	WO 00/32174
//(A61K 31/54, 31:40)	AS	(43) International Publication Date:	8 June 2000 (08.06.00)
 (21) International Application Number: PCT/EP (22) International Filing Date: 20 November 1999 ((30) Priority Data: 98122489.2 27 November 1998 (27.11.9 (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/O Grenzacherstrasse, CH-4070 Basle (CH). (72) Inventor: HELLER, Rudolf; Lindenberg 7, A-2123 (AT). (74) Agent: WITTE, Hubert; 124, Grenzacherstrasse, Basle (CH). 	20.11.9 28) CH]; 12 Traunfe CH-40	BR, BY, CA, CH, CN, CU, CZ, GD, GE, GH, GM, HR, HU, ID KP, KR, KZ, LC, LK, LR, LS, L' MK, MN, MW, MX, NO, NZ, ISG, SI, SK, SL, TJ, TM, TR, TZA, ZW, ARIPO patent (GH, GSZ, TZ, UG, ZW), Eurasian pater MD, RU, TJ, TM), European pater DK, ES, FI, FR, GB, GR, IE, I'OAPI patent (BF, BJ, CF, CG, CMR, NE, SN, TD, TG). Published With international search report. (88) Date of publication of the international files.	DE, DK, EE, ES, FI, GB, J, IL, IN, IS, IP, KE, KG, T, LU, LV, MA, MD, MG, PL, PT, RO, RU, SD, SE, T, UA, UG, UZ, VN, YU, M, KE, LS, MW, SD, SL, nt (AM, AZ, BY, KG, KZ, ent (AT, BE, CH, CY, DE, T, LU, MC, NL, PT, SE), I, CM, GA, GN, GW, ML, onal search report: November 2000 (16.11.00)
(54) Title: PHARMACEUTICAL COMBINATION PREI	PARAT	TONS OF CARVEDILOL AND HYDROCHLO	OROTHIAZIDE

(57) Abstract

The present invention is concerned with a pharmaceutical combination preparation for the treatment of cardiac and cardiovascular disorders such as hypertension, angina pectoris, cardiac insufficiency and illnesses associated therewith, containing the active substances carvedilol or a pharmaceutically acceptable salt thereof and hydrochlorothiazide or a pharmaceutically acceptable salt thereof as well as pharmaceutically usual additives.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Inter nal Application No PCT/EP 99/08972

a. classification of subject matter IPC 7 A61K31/54 A61K31/403

A61K9/28

//(A61K31/54,31:40)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\frac{\text{Minimum documentation searched (classification system followed by classification symbols)}}{IPC~7~A61K}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBASE, MEDLINE, EPO-Internal, BIOSIS, CHEM ABS Data, CANCERLIT, PAJ, WPI Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BISTON P. ET AL: "Carvedilol in the treatment of mild to moderate hypertension: Experience with ambulatory blood pressure monitoring." ACTA CARDIOLOGICA, (1994) 49/2 (145-155)., XP000904756 page 146, paragraph 5 page 154, paragraph 3	1-4,7,8
X	RUDORF J.E. ET AL: "Pharmacokinetic and pharmacodynamic interactions of combined acute administration of carvedilol and hydrochlorothiazide in hypertensive volunteers." DRUGS, (1988) 36/SUPPL. 6 (113-117)., XP000904788 page 117, column 1, paragraph 2 -column 2, paragraph 1	1-4,7,8

Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search 22 August 2000	Date of mailing of the international search report 0.5. 09. 2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Marttin, E

Inter onal Application No
PCT/EP 99/08972

		PC1/EP 99/089/2
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DUPONT A G ET AL: "The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics." EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, (1990) 38 SUPPL 2 S153-7., XP000904769 page 157, column 1, paragraph 2	1-4,7,8
X	WIDMANN L ET AL: "Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide." EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, (1990) 38 SUPPL 2 S143-6., XP000904786 figure 1 page 145, column 2, paragraph 6 -page 146, column 2, paragraph 1	1-4,7,8
X	WO 96 24348 A (BOEHRINGER MANNHEIM PHARM CORP ;LUKAS LASKEY MARY ANN (US); RUFFOL) 15 August 1996 (1996-08-15) page 9, line 9 - line 26	1-4,7,8
X	DE 196 37 082 A (BOEHRINGER MANNHEIM GMBH) 19 March 1998 (1998-03-19) page 2, line 65 - last line page 3, line 7 - line 9 page 3, line 24 - line 32 page 3, line 46 - line 55; claims 1-3,5,7,10; examples 1-19,21-25	18,19,22
X	WO 98 05320 A (BENKERROUR LOUTFY; JOUVEINAL LAB (FR); DOAT BERNARD (FR)) 12 February 1998 (1998-02-12) page 8, line 10 - line 25; claims 1-6; example 1	18,22 19
Х	US 5 425 950 A (DANDIKER YOGENDRA ET AL)	18,22
А	20 June 1995 (1995-06-20) column 3, line 17 - line 33 column 6, line 5 - line 32; claims 1,2,8,9; examples 1,2,4,9	19
A	THOENNES C J ET AL: "EVALUATION OF A RAPIDLY DISINTEGRATING MOISTURE RESISTANT LACQUER FILM COATING" DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 15, no. 2, 1989, pages 165-186, XP000938464 ISSN: 0363-9045 abstract page 166, paragraph 2; table 3 -/	20-22

5

Inter nal Application No PCT/EP 99/08972

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Helevant to claim No.
A	"Eudragit E30D Anwendung in der Arzneimittelherstellung" May 1981 (1981-05), RÖHM PHARMA, WEITERSTAT XP002145397 page 4, column 2, line 1 -page 5, column 2, last line	20-22
A	US 5 019 398 A (DASTE GEORGES) 28 May 1991 (1991-05-28) column 2, line 47 - line 63; claims; examples	20-22

5

International application No. PCT/EP 99/08972

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sneet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 8 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: - because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claim 22 does not meet the requirements of Article 6 PCT in that the subject-matter for which protection is sought is not clearly defined. A lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely claim 22 insofar a composition according to claims 1-21 was concerned.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-17, 22 (partially)

The problem to be solved by the present application is to provide a pharmaceutical combination for the treatment of cardiac or cardiovascular disorders.

The solution to this problem proposed in the present application is to use a combination containing the active substances carvediol or a pharmaceutically acceptable salt thereof and hydrochlorothiazide or a pharmaceutically acceptable salt thereof.

The subject matters of claim 18-19 or 20-21 are no solutions to the mentioned problem: These claims are concerned with a pharmaceutically acceptable solid dosage form having a disintegrant content of at least 5 weight% or with a light-protecting film suspension.

The idea to use a combination of carvediol and hydrochlorothiazide is known in the state of the art (see the documents cited in the search report), and cannot serve as a single inventive concept, linking the different inventions.

In the present application no further technical features can be distinguished that can be regarded as a "special technical feature" involved in the technical relationship among the different inventions. Consequently, the present application lacks unity of invention, and the different solutions not belonging to a common inventive concept are identified as the different subjects listed above.

Searching these different subjects would have caused a major additional searching effort. Only the first subject was searched.

2. Claim: 18 19 22 (partially)

A pharmaceutically acceptable solid dosage form having a disintegrant content of at least 5 weight%

3. Claim: 20 21 22 (partially)

A light-protecting film suspension.

Inter Inal Application No
PCT/EP 99/08972

		<u>-</u> -	-	Τ			99/089/2
	tent document in search report		Publication date		Patent family member(s)	<i>'</i>	Publication date
WO	9624348	A	15-08-1996	DE UST AU AU BR CCZ DE DE ES FI FI SK US	7021 47181 96071 22125 11851 97024 696024 08081 21345 9732 30309 99007 105134 9736 3217 8081	069 A 891 T 106 B 111 A 548 A 106 A 124 D 124 T 162 A 773 A	22-08-1996 02-06-1998 15-05-1999 11-02-1999 27-08-1996 04-11-1997 15-08-1996 17-06-1998 11-11-1998 17-06-1999 07-10-1999 26-11-1997 01-10-1999 07-08-1997 30-11-1999 28-07-1999 22-12-1998 08-08-1997 22-12-1997 31-10-1999 10-03-1999 11-05-1999
DE	19637082	Α	19-03-1998	AU CN WO EP ZA	1237: 9810: 0925(997 A 104 A 754 A 060 A	02-04-1998 01-12-1999 19-03-1998 30-06-1999 11-03-1999
WO	9805320	A	12-02-1998	FR AU BR CA CN CZ EP ES GR HU IT PL	36970 97110 22562 12262 99003 09422 21300 10023 99023 GE9700 3311	162 A 097 A 032 A 751 A 162 A 376 A 718 A 081 A 907 B 878 A 067 A 517 A	13-02-1998 25-02-1998 17-08-1999 12-02-1998 18-08-1999 12-05-1999 22-09-1999 16-06-1999 13-05-1998 28-04-2000 08-02-1999 19-07-1999 27-02-1998
US	5425950	A	20-06-1995	AU AU BE CA CH CZ DE EP ES FR GB IT JP LU	2746 1005 2081 685 9203 69222 69222 0546 2106 2683 2262 1263 5194		29-02-1996 06-05-1993 10-08-1993 01-05-1993 15-08-1995 13-10-1993 09-10-1997 22-01-1998 16-06-1993 16-11-1997 07-05-1993 23-06-1993 05-08-1996 03-08-1993 17-05-1993

Inter anal Application No PCT/EP 99/08972

Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
US 5425950	A		MX NO NZ ZA	9206236 A 924183 A 244921 A 9208359 A	01-04-1993 03-05-1993 27-04-1995 13-08-1993	
US 5019398	Α	28-05-1991	FR AU AU CA DE DE EP NZ	2643556 A 623225 B 4999890 A 2010427 A 69000881 D 69000881 T 0385846 A 232649 A	31-08-1990 07-05-1992 30-08-1990 27-08-1990 25-03-1993 12-08-1993 05-09-1990 29-01-1991	